RT Journal Article
SR Electronic
T1 Co-trifamole (co-fram)
JF Drug and Therapeutics Bulletin
JO Drug Ther Bull
FD BMJ Publishing Group Ltd
SP 19
OP 20
DO 10.1136/dtb.21.5.19
VO 21
IS 5
YR 1983
UL http://dtb.bmj.com/content/21/5/19.abstract
AB Co-trifamole (Co-Fram - Abbott) is a new combination of a sulphonamide, sulphamoxole, and trimethoprim for oral use. It is similar to co-trimoxazole (sulphamethoxazole + trimethoprim; various brands) and co-trimazine (sulphadiazine + trimethoprim; Coptin),1 which has recently been withdrawn from the UK market. The manufacturer claims co-trifamole to be effective in lower dosage and therefore with fewer dose-dependent adverse effects.